ProfileGDS5678 / 1443206_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 39% 39% 35% 44% 43% 38% 39% 38% 55% 39% 37% 39% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.675661
GSM967853U87-EV human glioblastoma xenograft - Control 22.8851139
GSM967854U87-EV human glioblastoma xenograft - Control 32.8873439
GSM967855U87-EV human glioblastoma xenograft - Control 42.7323335
GSM967856U87-EV human glioblastoma xenograft - Control 52.9870444
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0892343
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9202238
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8739
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8490838
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3682755
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8809139
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8104337
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.893339
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8847339